130 related articles for article (PubMed ID: 31914200)
1. The Future of CAR T-Cell Therapy.
Slater H
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914200
[No Abstract] [Full Text] [Related]
2. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
Porter DL
Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
[No Abstract] [Full Text] [Related]
3. CAR T-cell therapy in refractory large B-cell lymphoma.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
[No Abstract] [Full Text] [Related]
4. Cellular Immunotherapy in B-Cell Malignancy.
Schwarzbich MA; Witzens-Harig M
Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
[TBL] [Abstract][Full Text] [Related]
5. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019.
Lemal R; Tournilhac O
J Immunother Cancer; 2019 Aug; 7(1):202. PubMed ID: 31370892
[TBL] [Abstract][Full Text] [Related]
6. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
7. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
8. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model.
Tully S; Feng Z; Grindrod K; McFarlane T; Chan KKW; Wong WWL
JCO Clin Cancer Inform; 2019 Oct; 3():1-9. PubMed ID: 31644324
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
Todorovic Z; Todorovic D; Markovic V; Ladjevac N; Zdravkovic N; Djurdjevic P; Arsenijevic N; Milovanovic M; Arsenijevic A; Milovanovic J
Curr Oncol; 2022 May; 29(5):3647-3657. PubMed ID: 35621683
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
11. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
13. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
[No Abstract] [Full Text] [Related]
14. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
15. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
16. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
18. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
19. Safety of CAR T-cell therapy in kidney transplant recipients.
Mamlouk O; Nair R; Iyer SP; Edwards A; Neelapu SS; Steiner RE; Adkins SA; Hawkins M; Saini N; Devashish K; Strati P; Mandayam S; Ahmed S
Blood; 2021 May; 137(18):2558-2562. PubMed ID: 33512386
[No Abstract] [Full Text] [Related]
20. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]